DTL
FHTX icon

Dynamic Technology Lab’s Foghorn Therapeutics FHTX Stock Holding History

Dynamic Technology Lab’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-20,551
Closed -$279K – 1249
2022
Q2 		$279K Buy
+20,551
New +$265K 0.03% 791

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Dynamic Technology Lab's FHTX Position: Q3 2022 in Review

Dynamic Technology Lab sold out of Foghorn Therapeutics (FHTX) in Q3 2022, closing a stake of 20,551 shares — an estimated $279K sold.

Dynamic Technology Lab first reported a position in FHTX in Q2 2022 and held it in 1 quarter. The position peaked at $279K in Q2 2022. 62 funds tracked by Wall St. Rank hold FHTX as of Q3 2022.

  • Dynamic Technology Lab reported no remaining Foghorn Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Dynamic Technology Lab sold 20,551 Foghorn Therapeutics shares in Q3 2022, an estimated $279K.
  • Dynamic Technology Lab first reported a position in Foghorn Therapeutics in Q2 2022 and held it in 1 quarter.
  • Dynamic Technology Lab's Foghorn Therapeutics position peaked at $279K in Q2 2022.
  • 62 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q3 2022.

Based on Dynamic Technology Lab's 13F filing for Q3 2022, filed 14 Nov 2022.